BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma. The data were featured this week in a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.
